Cargando…
Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran
BACKGROUND: Opioid agonist therapy (OAT) uptake has been associated with multiple positive health outcomes among people who inject drugs (PWID). This study evaluated the pattern of OAT uptake among PWID in two consecutive national bio-behavioral surveillance surveys (2010 and 2014) in Iran. METHODS:...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373839/ https://www.ncbi.nlm.nih.gov/pubmed/32698875 http://dx.doi.org/10.1186/s12954-020-00392-1 |
_version_ | 1783561569958887424 |
---|---|
author | Nakhaeizadeh, Mehran Abdolahinia, Zahra Sharifi, Hamid Mirzazadeh, Ali Haghdoost, Ali Akbar Shokoohi, Mostafa Baral, Stefan Karamouzian, Mohammad Shahesmaeili, Armita |
author_facet | Nakhaeizadeh, Mehran Abdolahinia, Zahra Sharifi, Hamid Mirzazadeh, Ali Haghdoost, Ali Akbar Shokoohi, Mostafa Baral, Stefan Karamouzian, Mohammad Shahesmaeili, Armita |
author_sort | Nakhaeizadeh, Mehran |
collection | PubMed |
description | BACKGROUND: Opioid agonist therapy (OAT) uptake has been associated with multiple positive health outcomes among people who inject drugs (PWID). This study evaluated the pattern of OAT uptake among PWID in two consecutive national bio-behavioral surveillance surveys (2010 and 2014) in Iran. METHODS: Data were obtained from two national bio-behavioral surveillance surveys (N(2010) = 1783 and N(2014) = 2166) implemented using convenience sampling at the harm reduction facilities and street venues in 10 geographically diverse urban centers across Iran. Multivariable logistic regression models were built to determine the correlates of OAT uptake for the 2014 survey, and adjusted odds ratios (AORs) along with 95% confidence intervals (CI) were reported. RESULTS: The prevalence of OAT uptake decreased from 49.2% in 2010 to 45.8% in 2014 (P value = 0.033). OAT uptake varied across the studied cities ranging from 0.0 to 69.3% in the 2010 survey and 3.2 to 75.5% in the 2014 survey. Ever being married (AOR = 1.40; 95% CI 1.12, 1.75), having a history of incarceration (AOR = 1.56; 95% CI 1.16, 2.09), and human immunodeficiency virus (HIV) sero-positivity (AOR = 1.63; 95% CI 1.08, 2.50) were associated with OAT uptake. Conversely, PWID who reported using only non-opioid drugs (AOR = 0.43; 95% CI 0.26, 0.71) and those who reported concurrent use of opioid and non-opioid drugs (AOR = 0.66; 95% CI 0.51, 0.86) were less likely to uptake OAT. CONCLUSIONS: Although OAT uptake among PWID in Iran is above the 40% threshold defined by the World Health Organization, there remain significant disparities across urban settings in Iran. Importantly, the OAT services appear to be serving high-risk PWID including those living with HIV and those with a history of incarceration. Evaluating service integration including mental health, HIV and hepatitis C virus care, and other harm reduction services may support the optimization of health outcomes associated with OAT across Iran. |
format | Online Article Text |
id | pubmed-7373839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73738392020-07-22 Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran Nakhaeizadeh, Mehran Abdolahinia, Zahra Sharifi, Hamid Mirzazadeh, Ali Haghdoost, Ali Akbar Shokoohi, Mostafa Baral, Stefan Karamouzian, Mohammad Shahesmaeili, Armita Harm Reduct J Research BACKGROUND: Opioid agonist therapy (OAT) uptake has been associated with multiple positive health outcomes among people who inject drugs (PWID). This study evaluated the pattern of OAT uptake among PWID in two consecutive national bio-behavioral surveillance surveys (2010 and 2014) in Iran. METHODS: Data were obtained from two national bio-behavioral surveillance surveys (N(2010) = 1783 and N(2014) = 2166) implemented using convenience sampling at the harm reduction facilities and street venues in 10 geographically diverse urban centers across Iran. Multivariable logistic regression models were built to determine the correlates of OAT uptake for the 2014 survey, and adjusted odds ratios (AORs) along with 95% confidence intervals (CI) were reported. RESULTS: The prevalence of OAT uptake decreased from 49.2% in 2010 to 45.8% in 2014 (P value = 0.033). OAT uptake varied across the studied cities ranging from 0.0 to 69.3% in the 2010 survey and 3.2 to 75.5% in the 2014 survey. Ever being married (AOR = 1.40; 95% CI 1.12, 1.75), having a history of incarceration (AOR = 1.56; 95% CI 1.16, 2.09), and human immunodeficiency virus (HIV) sero-positivity (AOR = 1.63; 95% CI 1.08, 2.50) were associated with OAT uptake. Conversely, PWID who reported using only non-opioid drugs (AOR = 0.43; 95% CI 0.26, 0.71) and those who reported concurrent use of opioid and non-opioid drugs (AOR = 0.66; 95% CI 0.51, 0.86) were less likely to uptake OAT. CONCLUSIONS: Although OAT uptake among PWID in Iran is above the 40% threshold defined by the World Health Organization, there remain significant disparities across urban settings in Iran. Importantly, the OAT services appear to be serving high-risk PWID including those living with HIV and those with a history of incarceration. Evaluating service integration including mental health, HIV and hepatitis C virus care, and other harm reduction services may support the optimization of health outcomes associated with OAT across Iran. BioMed Central 2020-07-22 /pmc/articles/PMC7373839/ /pubmed/32698875 http://dx.doi.org/10.1186/s12954-020-00392-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Nakhaeizadeh, Mehran Abdolahinia, Zahra Sharifi, Hamid Mirzazadeh, Ali Haghdoost, Ali Akbar Shokoohi, Mostafa Baral, Stefan Karamouzian, Mohammad Shahesmaeili, Armita Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran |
title | Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran |
title_full | Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran |
title_fullStr | Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran |
title_full_unstemmed | Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran |
title_short | Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran |
title_sort | opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in iran |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373839/ https://www.ncbi.nlm.nih.gov/pubmed/32698875 http://dx.doi.org/10.1186/s12954-020-00392-1 |
work_keys_str_mv | AT nakhaeizadehmehran opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT abdolahiniazahra opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT sharifihamid opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT mirzazadehali opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT haghdoostaliakbar opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT shokoohimostafa opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT baralstefan opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT karamouzianmohammad opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran AT shahesmaeiliarmita opioidagonisttherapyuptakeamongpeoplewhoinjectdrugsthefindingsoftwoconsecutivebiobehavioralsurveillancesurveysiniran |